000144745 001__ 144745
000144745 005__ 20240229112636.0
000144745 0247_ $$2doi$$a10.6004/jnccn.2019.7287
000144745 0247_ $$2pmid$$apmid:31487678
000144745 0247_ $$2ISSN$$a1540-1405
000144745 0247_ $$2ISSN$$a1540-1413
000144745 0247_ $$2altmetric$$aaltmetric:66390049
000144745 037__ $$aDKFZ-2019-02177
000144745 041__ $$aeng
000144745 082__ $$a610
000144745 1001_ $$0P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aWalter, Viola$$b0$$eFirst author$$udkfz
000144745 245__ $$aDecreasing Use of Chemotherapy in Older Patients With Stage III Colon Cancer Irrespective of Comorbidities.
000144745 260__ $$aCold Spring Harbor, NY$$bHarborside Press$$c2019
000144745 3367_ $$2DRIVER$$aarticle
000144745 3367_ $$2DataCite$$aOutput Types/Journal article
000144745 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577105995_18928
000144745 3367_ $$2BibTeX$$aARTICLE
000144745 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144745 3367_ $$00$$2EndNote$$aJournal Article
000144745 520__ $$aChemotherapy underuse in elderly patients (aged ≥75 years) with colon cancer has been reported in previous studies. However, these studies were mostly registry-based and limited in their potential to consider underlying reasons of such undertreatment. This study aimed to evaluate patient and hospital determinants of chemotherapeutic treatment in patients with stage III colon cancer, with a particular focus on age and underlying reasons for nontreatment of elderly patients.A total of 629 patients with stage III colon cancer who were diagnosed in 2003 through 2012 and recruited into a population-based study in the Rhine-Neckar region of Germany were included. Information on sociodemographic and lifestyle factors, comorbidities, and treatment was collected from patient interviews and physicians. Patient (with an emphasis on age) and hospital factors were evaluated for their associations with administration of adjuvant chemotherapy overall and of oxaliplatin specifically using multivariable logistic regression.Administration of chemotherapy decreased from 94% in patients aged 30 to 64 years to 51% in those aged ≥75 years. A very strong decline in chemotherapy use with age persisted even after comprehensive adjustment for multiple patient factors-including comorbidities-and hospital factors and was also seen among patients without any major comorbidities. Between 2005 and 2008, and 2009 and 2012, chemotherapy administration in patients aged ≥75 years decreased from 60% to 41%. Among chemotherapy recipients, old age was also strongly associated with higher odds of nonadministration of oxaliplatin. The 2 most commonly reported reasons for chemotherapy nonreceipt among the study population were patient refusal (30%) and old age (24%).Age was the strongest predictor of chemotherapy underuse, irrespective of comorbidities and even in patients without comorbidities. Such underuse due just to older age in otherwise healthy patients deserves increased attention in clinical practice to ensure that elderly patients also get the best possible care. Patients' refusal as the most frequent reason for chemotherapy nonreceipt also warrants further investigation to exclude misinformation as underlying cause.
000144745 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144745 588__ $$aDataset connected to CrossRef, PubMed,
000144745 7001_ $$0P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aBoakye, Daniel$$b1$$udkfz
000144745 7001_ $$0P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aWeberpals, Janick$$b2$$udkfz
000144745 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b3$$udkfz
000144745 7001_ $$aHaefeli, Walter E$$b4
000144745 7001_ $$aMartens, Uwe M$$b5
000144745 7001_ $$aKnebel, Phillip$$b6
000144745 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b7$$udkfz
000144745 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$udkfz
000144745 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author$$udkfz
000144745 773__ $$0PERI:(DE-600)2134524-7$$a10.6004/jnccn.2019.7287$$gVol. 17, no. 9, p. 1089 - 1099$$n9$$p1089 - 1099$$tJournal of the National Comprehensive Cancer Network$$v17$$x1540-1413$$y2019
000144745 909CO $$ooai:inrepo02.dkfz.de:144745$$pVDB
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf5409aed74a0923d9402c2c7ad620aa$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000144745 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000144745 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144745 9141_ $$y2019
000144745 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NATL COMPR CANC NE : 2017
000144745 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144745 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144745 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144745 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144745 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144745 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144745 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NATL COMPR CANC NE : 2017
000144745 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000144745 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000144745 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x2
000144745 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000144745 980__ $$ajournal
000144745 980__ $$aVDB
000144745 980__ $$aI:(DE-He78)C070-20160331
000144745 980__ $$aI:(DE-He78)C120-20160331
000144745 980__ $$aI:(DE-He78)C020-20160331
000144745 980__ $$aI:(DE-He78)L101-20160331
000144745 980__ $$aUNRESTRICTED